Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has received an average recommendation of “Hold” from the seven brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $24.73.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. BidaskClub raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Finally, TheStreet downgraded shares of Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, November 7th.
In other Amphastar Pharmaceuticals news, General Counsel Jason B. Shandell sold 8,205 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $19.13, for a total value of $156,961.65. Following the completion of the transaction, the general counsel now directly owns 138,898 shares of the company’s stock, valued at approximately $2,657,118.74. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Jason B. Shandell sold 25,000 shares of the firm’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $18.44, for a total transaction of $461,000.00. Following the completion of the transaction, the general counsel now directly owns 163,898 shares of the company’s stock, valued at $3,022,279.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,205 shares of company stock valued at $656,467. Insiders own 30.80% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its position in shares of Amphastar Pharmaceuticals by 1.2% in the third quarter. California State Teachers Retirement System now owns 55,912 shares of the company’s stock valued at $1,109,000 after acquiring an additional 668 shares during the period. Prudential Financial Inc. boosted its stake in Amphastar Pharmaceuticals by 1.4% during the second quarter. Prudential Financial Inc. now owns 63,076 shares of the company’s stock worth $1,331,000 after acquiring an additional 870 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Amphastar Pharmaceuticals by 15.4% during the second quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock worth $205,000 after acquiring an additional 1,314 shares in the last quarter. Rhumbline Advisers boosted its stake in Amphastar Pharmaceuticals by 1.3% during the third quarter. Rhumbline Advisers now owns 108,931 shares of the company’s stock worth $2,160,000 after acquiring an additional 1,358 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in Amphastar Pharmaceuticals by 130.7% during the second quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock worth $104,000 after acquiring an additional 2,789 shares in the last quarter. 51.27% of the stock is owned by hedge funds and other institutional investors.
Shares of AMPH remained flat at $$20.08 on Wednesday. 223,903 shares of the company were exchanged, compared to its average volume of 158,926. The company has a quick ratio of 1.84, a current ratio of 3.11 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a 12 month low of $16.71 and a 12 month high of $25.43. The firm has a market cap of $942.52 million, a PE ratio of 19.12 and a beta of 1.16. The company has a fifty day moving average of $19.22 and a two-hundred day moving average of $19.95.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.02. The firm had revenue of $80.14 million during the quarter, compared to analyst estimates of $78.53 million. Amphastar Pharmaceuticals had a net margin of 15.77% and a return on equity of 5.07%. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter last year, the business posted $0.12 EPS. Equities research analysts forecast that Amphastar Pharmaceuticals will post 0.05 EPS for the current fiscal year.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.
See Also: Google Finance Portfolio
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.